Experienced in Monkeypox

Christoph D. Spinner

Ismaninger Str. 22, 
Munich, BY, DE 
Experienced in Monkeypox
Ismaninger Str. 22, 
Munich, BY, DE 
OverviewLocationsClinical Research

Overview

Christoph Spinner practices in Munich, Germany. Mr. Spinner is rated as an Experienced expert by MediFind in the treatment of Monkeypox. His top areas of expertise are HIV/AIDS, Severe Acute Respiratory Syndrome (SARS), COVID-19, Spontaneous Bacterial Peritonitis, and Tissue Biopsy.

His clinical research consists of co-authoring 190 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Monkeypox.

Gender
Male

Locations

Ismaninger Str. 22, Munich, BY 81675, Germany
Other Locations
Biedersteiner Str. 29, Munich, BY 80802, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2-Drug Regimen Juluca, a Onepill-Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany
Enrollment Status: Completed
Publish Date: October 16, 2024
Intervention Type: Drug
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients With Advanced HIV Disease
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Biktarvy, Symtuza
Study Phase: Phase 3
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
A Phase IIb, Randomized, Partially Blind, Active Controlled, Dose-range Finding Study of GSK3640254 Compared to a Reference Arm of Dolutegravir, Each in Combination With Nucleoside Reverse Transcriptase Inhibitors, in HIV-1 Infected Antiretroviral Treatment-naive Adults
Enrollment Status: Terminated
Publish Date: June 26, 2024
Intervention Type: Drug
Study Drugs: GSK3640254, ABC/3TC, FTC/TAF, Dolutegravir
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
A Phase III, Randomized, Multicenter, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
Enrollment Status: Completed
Publish Date: May 30, 2024
Intervention Type: Drug
Study Drugs: Gepotidacin, Ceftriaxone, Azithromycin
Study Phase: Phase 3
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
A Phase IIb, Randomized, Double-blind, Parallel-group Study to Assess the Efficacy, Safety, Tolerability, and Resistance Profile of GSK3640254 in Combination With Dolutegravir Compared to Dolutegravir Plus Lamivudine in HIV-1 Infected, Treatment-naïve Adults
Enrollment Status: Terminated
Publish Date: December 14, 2023
Intervention Type: Drug
Study Drugs: GSK3640254, Dolutegravir, Lamivudine
Study Phase: Phase 2
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2
Study to Identify Differences of Exhaled Breath Components Using Ion Mobility Spectrometry (IMS) in Patients Tested Positive or Negative on SARS-CoV-2
Enrollment Status: Completed
Publish Date: July 08, 2021
Intervention Type: Device
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Enrollment Status: Completed
Publish Date: July 06, 2021
Intervention Type: Drug
Study Drug: Sofosbuvir+Velpatasvir
Study Phase: Phase 2
A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults
A Randomized, Double-Blind (Sponsor-unblinded), Placebo-Controlled, Adaptive Trial to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK3640254 in HIV-1 Infected Treatment-Naïve Adults
Enrollment Status: Completed
Publish Date: February 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

189 Total Publications

Cardiovascular risk and achievement of target levels in low-density lipoprotein cholesterol in people living with HIV: insights from the DUALIS study.
Cardiovascular risk and achievement of target levels in low-density lipoprotein cholesterol in people living with HIV: insights from the DUALIS study.
Journal: HIV research & clinical practice
Published: July 23, 2025
View All 189 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Spinner's expertise for a condition
ConditionClose
    • Distinguished
    • COVID-19
      Mr. Spinner is
      Distinguished
      . Learn about COVID-19.
      See more COVID-19 experts
    • HIV/AIDS
      Mr. Spinner is
      Distinguished
      . Learn about HIV/AIDS.
      See more HIV/AIDS experts
    • Severe Acute Respiratory Syndrome (SARS)
      Mr. Spinner is
      Distinguished
      . Learn about Severe Acute Respiratory Syndrome (SARS).
      See more Severe Acute Respiratory Syndrome (SARS) experts
    • Advanced
    • Ascites
      Mr. Spinner is
      Advanced
      . Learn about Ascites.
      See more Ascites experts
    • Hepatitis C
      Mr. Spinner is
      Advanced
      . Learn about Hepatitis C.
      See more Hepatitis C experts
    • Pneumonia
      Mr. Spinner is
      Advanced
      . Learn about Pneumonia.
      See more Pneumonia experts
    • Spontaneous Bacterial Peritonitis
      Mr. Spinner is
      Advanced
      . Learn about Spontaneous Bacterial Peritonitis.
      See more Spontaneous Bacterial Peritonitis experts
    • Experienced
    • Acute Respiratory Distress Syndrome (ARDS)
      Mr. Spinner is
      Experienced
      . Learn about Acute Respiratory Distress Syndrome (ARDS).
      See more Acute Respiratory Distress Syndrome (ARDS) experts
    • Aspergillosis
      Mr. Spinner is
      Experienced
      . Learn about Aspergillosis.
      See more Aspergillosis experts
    • Asymptomatic Bacteriuria
      Mr. Spinner is
      Experienced
      . Learn about Asymptomatic Bacteriuria.
      See more Asymptomatic Bacteriuria experts
    • B-Cell Lymphoma
      Mr. Spinner is
      Experienced
      . Learn about B-Cell Lymphoma.
      See more B-Cell Lymphoma experts
    • Bacterial Meningitis
      Mr. Spinner is
      Experienced
      . Learn about Bacterial Meningitis.
      See more Bacterial Meningitis experts
    • Brain Abscess
      Mr. Spinner is
      Experienced
      . Learn about Brain Abscess.
      See more Brain Abscess experts
    View All 40 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved